Weight Change in Patients with Psoriasis using Tumor Necrosis Factor-Alpha Inhibitors.
Journal: 2019/September - British Journal of Dermatology
ISSN: 1365-2133
Abstract:
Psoriasis is a chronic, inflammatory, immune-mediated disease, characterized by erythematous scaly plaques occurring in about 2-3% of the population. TNF- α plays a role not only in the inflammatory cascade but also in body weight homeostasis which could be disrupted by TNF-α inhibitors, such as adalimumab, infliximab, and etanercept, used for treatment of moderate-severe psoriasis. The goal of this study is to determine the association between the use of TNF-α inhibitors and weight gain in patients with plaque psoriasis based on available clinical trials. This article is protected by copyright. All rights reserved.
Relations:
Citations
(1)
Diseases
(1)
Conditions
(4)
Drugs
(5)
Genes
(1)
Processes
(1)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.